ArticleProceedings of the National Academy of Sciences of the United States of America2019
Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Generation and Characterization of a Rdh1-iCre Line to Study Uterine Glandular Biology.Genesis (New York, N.Y. : 2000) · 2026Article
- Co-mutations of CTNNB1 and PTEN drive aggressive tumor progression in endometrial cancer.Disease models & mechanisms · 2026Article
- YAP1 activates SLC2A1 transcription and augments the malignant behavior of colorectal cancer cells by activating the Wnt/β-catenin signaling pathway.Cell division · 2025Article
- UterineCancers · 2025Article
- Article
- Seminal plasma exosome derived miR-26-5p can regulate decidual macrophage polarization via PTEN / PI3K / AKT signaling pathway.Scientific reports · 2025Article
- KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer.British journal of cancer · 2024Article
- Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression.Journal of translational medicine · 2023Article
- Transient and DNA-free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis.Cancer communications (London, England) · 2023Article
- Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non-invasive vaginal swab.Journal of cellular and molecular medicine · 2023Article
- Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial Cancer.JCO precision oncology · 2022Article
- Tailored Therapy Based on Molecular Characteristics in Endometrial Cancer.BioMed research international · 2021Review
- SIX1 cooperates with RUNX1 and SMAD4 in cell fate commitment of Müllerian duct epithelium.Cell death and differentiation · 2020Article
- Article
- Clinical actionability of molecular targets in endometrial cancer.Nature reviews. Cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Endometrioid endometrial carcinomas (EECs) carry multiple driver mutations even when they are low grade. However, the biological significance of these concurrent mutations is unknown. We explored the interactions among three signature EEC mutations: loss-of-function (LOF) mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.